NF-κB activation in development and progression of cancer

Jun Ichiro Inoue, Jin Gohda, Taishin Akiyama, Kentaro Senba

Research output: Contribution to journalArticle

183 Citations (Scopus)

Abstract

Nuclear factor-κB (NF-κB) binds specifically to NF-κB-binding sites (κB sites, 5′-GGGRNNYYCC-3′ R, purine; Y, pyrimidine; N, any nucleotide) present in enhancer regions of various genes. Binding of various cytokines, growth factors and pathogen-associated molecular patterns to specific receptors activates NF-κB and expression of genes that play critical roles in inflammation, innate and acquired immunity, bone remodeling and generation of skin appendices. Activation of NF-κB is also involved in cancer development and progression. NF-κB is activated in cells that become malignant tumors and in cells that are recruited to and constitute the tumor microenvironment. In the latter scenario, the TLR-TRAF6-NF-kB pathways seem to play major roles, and NF-κB activation results in production of cytokines, which in turn induce NF-κB activation in premalignant cells, leading to expression of genes involved abnormal growth and malignancy. Furthermore, NF-κB activation is involved in bone metastasis. Osteoclasts, whose generation requires the RANK-TRAF6-NF-κB pathways, release various growth factors stored in bone, which results in creation of microenvironment suitable for proliferation and colonization of cancer cells. Therefore, NF-κB and molecules involved its activation, such as TRAF6, are attractive targets for therapeutic strategies against cancer.

Original languageEnglish
Pages (from-to)268-274
Number of pages7
JournalCancer Science
Volume98
Issue number3
DOIs
Publication statusPublished - 2007 Mar
Externally publishedYes

Fingerprint

TNF Receptor-Associated Factor 6
Neoplasms
Intercellular Signaling Peptides and Proteins
Cytokines
Gene Expression
Bone and Bones
Tumor Microenvironment
NF-kappa B
Bone Remodeling
Adaptive Immunity
Osteoclasts
Cytoplasmic and Nuclear Receptors
Innate Immunity
Nucleotides
Binding Sites
Neoplasm Metastasis
Inflammation
Skin
Growth
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

NF-κB activation in development and progression of cancer. / Inoue, Jun Ichiro; Gohda, Jin; Akiyama, Taishin; Senba, Kentaro.

In: Cancer Science, Vol. 98, No. 3, 03.2007, p. 268-274.

Research output: Contribution to journalArticle

Inoue, Jun Ichiro ; Gohda, Jin ; Akiyama, Taishin ; Senba, Kentaro. / NF-κB activation in development and progression of cancer. In: Cancer Science. 2007 ; Vol. 98, No. 3. pp. 268-274.
@article{5738baff9ccd47e49d57f1f79804ace1,
title = "NF-κB activation in development and progression of cancer",
abstract = "Nuclear factor-κB (NF-κB) binds specifically to NF-κB-binding sites (κB sites, 5′-GGGRNNYYCC-3′ R, purine; Y, pyrimidine; N, any nucleotide) present in enhancer regions of various genes. Binding of various cytokines, growth factors and pathogen-associated molecular patterns to specific receptors activates NF-κB and expression of genes that play critical roles in inflammation, innate and acquired immunity, bone remodeling and generation of skin appendices. Activation of NF-κB is also involved in cancer development and progression. NF-κB is activated in cells that become malignant tumors and in cells that are recruited to and constitute the tumor microenvironment. In the latter scenario, the TLR-TRAF6-NF-kB pathways seem to play major roles, and NF-κB activation results in production of cytokines, which in turn induce NF-κB activation in premalignant cells, leading to expression of genes involved abnormal growth and malignancy. Furthermore, NF-κB activation is involved in bone metastasis. Osteoclasts, whose generation requires the RANK-TRAF6-NF-κB pathways, release various growth factors stored in bone, which results in creation of microenvironment suitable for proliferation and colonization of cancer cells. Therefore, NF-κB and molecules involved its activation, such as TRAF6, are attractive targets for therapeutic strategies against cancer.",
author = "Inoue, {Jun Ichiro} and Jin Gohda and Taishin Akiyama and Kentaro Senba",
year = "2007",
month = "3",
doi = "10.1111/j.1349-7006.2007.00389.x",
language = "English",
volume = "98",
pages = "268--274",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - NF-κB activation in development and progression of cancer

AU - Inoue, Jun Ichiro

AU - Gohda, Jin

AU - Akiyama, Taishin

AU - Senba, Kentaro

PY - 2007/3

Y1 - 2007/3

N2 - Nuclear factor-κB (NF-κB) binds specifically to NF-κB-binding sites (κB sites, 5′-GGGRNNYYCC-3′ R, purine; Y, pyrimidine; N, any nucleotide) present in enhancer regions of various genes. Binding of various cytokines, growth factors and pathogen-associated molecular patterns to specific receptors activates NF-κB and expression of genes that play critical roles in inflammation, innate and acquired immunity, bone remodeling and generation of skin appendices. Activation of NF-κB is also involved in cancer development and progression. NF-κB is activated in cells that become malignant tumors and in cells that are recruited to and constitute the tumor microenvironment. In the latter scenario, the TLR-TRAF6-NF-kB pathways seem to play major roles, and NF-κB activation results in production of cytokines, which in turn induce NF-κB activation in premalignant cells, leading to expression of genes involved abnormal growth and malignancy. Furthermore, NF-κB activation is involved in bone metastasis. Osteoclasts, whose generation requires the RANK-TRAF6-NF-κB pathways, release various growth factors stored in bone, which results in creation of microenvironment suitable for proliferation and colonization of cancer cells. Therefore, NF-κB and molecules involved its activation, such as TRAF6, are attractive targets for therapeutic strategies against cancer.

AB - Nuclear factor-κB (NF-κB) binds specifically to NF-κB-binding sites (κB sites, 5′-GGGRNNYYCC-3′ R, purine; Y, pyrimidine; N, any nucleotide) present in enhancer regions of various genes. Binding of various cytokines, growth factors and pathogen-associated molecular patterns to specific receptors activates NF-κB and expression of genes that play critical roles in inflammation, innate and acquired immunity, bone remodeling and generation of skin appendices. Activation of NF-κB is also involved in cancer development and progression. NF-κB is activated in cells that become malignant tumors and in cells that are recruited to and constitute the tumor microenvironment. In the latter scenario, the TLR-TRAF6-NF-kB pathways seem to play major roles, and NF-κB activation results in production of cytokines, which in turn induce NF-κB activation in premalignant cells, leading to expression of genes involved abnormal growth and malignancy. Furthermore, NF-κB activation is involved in bone metastasis. Osteoclasts, whose generation requires the RANK-TRAF6-NF-κB pathways, release various growth factors stored in bone, which results in creation of microenvironment suitable for proliferation and colonization of cancer cells. Therefore, NF-κB and molecules involved its activation, such as TRAF6, are attractive targets for therapeutic strategies against cancer.

UR - http://www.scopus.com/inward/record.url?scp=33846685017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846685017&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2007.00389.x

DO - 10.1111/j.1349-7006.2007.00389.x

M3 - Article

C2 - 17270016

AN - SCOPUS:33846685017

VL - 98

SP - 268

EP - 274

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 3

ER -